SCHEMBL1127447

SCHEMBL1127447

CCOC(=O)C(Cc1cccc(OC)c1)c1ccccn1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
GAA P10253 1/20 0.49
TAAR1 Q96RJ0 2/20 0.48
MAPK1 P28482 3/20 0.47
L3MBTL1 Q9Y468 3/20 0.47
ALDH1A1 P00352 3/20 0.47
TSHR P16473 2/20 0.47
TDP1 Q9NUW8 2/20 0.47
HPGD P15428 1/20 0.46
GRM4 Q14833 1/20 0.43
KDM4E B2RXH2 2/20 0.42
MAPT P10636 1/20 0.42
ADORA2A P29274 1/20 0.42
ADORA2B P29275 1/20 0.42
OPRD1 P41143 1/20 0.41
OPRK1 P41145 1/20 0.41
NR3C2 P08235 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1127831 0.92 KMT2A (0.45) KMT2AMEN1SMN1; SMN2GAATAAR1
SCHEMBL1127688 0.88 TAAR1 (0.50) KMT2AMEN1TAAR1GRM4NR3C2
SCHEMBL1127424 0.86 MEN1 (0.57) KMT2AMEN1SMN1; SMN2GAAL3MBTL1
SCHEMBL13662291 0.83 TAAR1 (0.45) KMT2AMEN1TAAR1TSHRHPGD
SCHEMBL27580463 0.83 KMT2A (0.52) KMT2AMEN1SMN1; SMN2GAAMAPK1
SCHEMBL1127494 0.81 KMT2A (0.51) KMT2AMEN1SMN1; SMN2GAAALDH1A1
SCHEMBL27142407 0.81 SMN1; SMN2 (0.46) KMT2AMEN1SMN1; SMN2GAAMAPK1
SCHEMBL1127832 0.80 TAAR1 (0.40) KMT2ATAAR1ALDH1A1TSHRHPGD
SCHEMBL1127513 0.80 KMT2A (0.50) KMT2AMEN1SMN1; SMN2GAAALDH1A1
SCHEMBL1127315 0.79 MEN1 (0.47) KMT2AMEN1SMN1; SMN2GAAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2283002-A2 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION Intermune, Inc. (US) 2011-02-16 EP disclosed
WO-2009134616-A2 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-11-05 WO disclosed
WO-2009134616-A2 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-11-05 WO disclosed
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication INTERMUNE, INC. (US) 2009-10-15 US disclosed
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication INTERMUNE, INC. (US) 2009-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication EIF2AK2, HAVCR2, HDGF KMT2A 2735/4885MEN1 4723/4885SMN1; SMN2 3563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.